title: Long-term outcome after radioiodine therapy with adjuvant rhTSH treatment: comparison between patients with non-toxic and pre-toxic large multinodular goitre.
abstract: In multinodular goitre (MNG), low radioiodine (RAI) activity after recombinant human (rh) TSH is able to reduce thyroid volume (TV) and improve symptoms. Our aim was to evaluate the long-term outcome of RAI after rhTSH treatment in patients who were divided according to their baseline TSH levels. Eighteen patients (69.2 ± 6.1 year) presented non-toxic (TSH >0.3 mIU/l) MNG (TV: 61.0 ± 3.8 ml; group 1), while 13 patients (74.1 ± 7.9 year) had non-autoimmune pre-toxic (TSH <0.3 mIU/l) MNG (TV: 82.6 ± 14.4 ml; group 2). TSH, thyroid hormones, TV (by ultrasonography), body mass index (BMI), symptoms and quality of life (QoL) were evaluated. Treatment induced short-term thyrotoxicosis in both groups, but this was slightly more marked in group 2 than in group 1. The number and severity of adverse events were similar. The follow-up period was 55.3 ± 4.1 months in group 1 and 57.2 ± 5.1 months in group 2. The final TV reduction was similar in groups 1 (63.4 ± 3.6%) and 2 (57.2 ± 4.6%) and TV reduction positively correlated only with initial TV. At the last examination, 14 group-1 subjects were on L-T4 therapy, while 2 group-2 subjects were on methimazole. An increase in BMI was noted only in group 2. MNG-related symptoms were significantly reduced in both groups. Symptoms related to sub-clinical hyperthyroidism improved in group 2, while no significant changes in QoL were noted in either group. This study confirms the effectiveness of rhTSH adjuvant treatment in reducing TV after low RAI activities, irrespective of baseline thyroid status. TSH levels <0.3 mIU/l proved to be predictive of a more severe thyrotoxic phase after rhTSH and RAI, while initial TSH levels >0.3 mIU/l were more frequently followed by a need for L-T4 therapy. Compressive symptoms improved in the majority of subjects.
authors.affiliation: Endocrine Unit, San Martino University Hospital, Genoa, Italy, magius@unige.it.
authors.forename: M
authors.initials: M
authors.lastname: Giusti
authors.forename: V
authors.initials: V
authors.lastname: Caorsi
authors.forename: L
authors.initials: L
authors.lastname: Mortara
authors.forename: M
authors.initials: M
authors.lastname: Caputo
authors.forename: E
authors.initials: E
authors.lastname: Monti
authors.forename: M
authors.initials: M
authors.lastname: Schiavo
authors.forename: M C
authors.initials: MC
authors.lastname: Bagnara
authors.forename: F
authors.initials: F
authors.lastname: Minuto
authors.forename: M
authors.initials: M
authors.lastname: Bagnasco
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D015992:Body Mass Index; D001835:Body Weight / Q000187:drug effects; D017024:Chemotherapy, Adjuvant; D005260:Female; D005500:Follow-Up Studies; D006044:Goiter, Nodular / Q000145:classification* / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D007457:Iodine Radioisotopes / Q000494:pharmacology / Q000627:therapeutic use*; D008137:Longitudinal Studies; D008297:Male; D008875:Middle Aged; D009929:Organ Size / Q000187:drug effects; D011788:Quality of Life; D013961:Thyroid Gland / Q000187:drug effects / Q000473:pathology*; D013972:Thyrotropin / Q000494:pharmacology / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D007457:Iodine Radioisotopes; D013972:Thyrotropin